Abstract
The systematic development of the RAPTA family of organometallic ruthenium(II) anticancer drugs containing a monodentate 1,3,5-triaza-7-phosphatricyclo-[3.3.1.1]decane (pta) ligand and a ?6-arene ligand is described.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
